Astrazeneca (AZN) EBT (2009 - 2026)

Astrazeneca has reported EBT for 18 years, with the latest figure at $2.8 billion in Q2 2026.

• On a quarterly basis, EBT fell 10.49% year-over-year to $2.8 billion in Q2 2026; TTM through Jun 2026 was $24.1 billion, a 140.03% increase from a year earlier, with the FY2025 full-year figure at $12.4 billion, up 42.7% from the prior year.
• EBT was $2.8 billion for Q2 2026 at Astrazeneca, down from $3.9 billion in the prior quarter.
• The five-year high for EBT was $14.1 billion in Q4 2025, with the low at $247.0 million in Q2 2022.
• Average EBT over 5 years is $3.0 billion, with a median of $2.3 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: EBT tumbled 72.24% in 2024, then jumped 746.4% in 2025.
• Over 5 years, EBT stood at $778.0 million in 2022, then jumped by 671.47% to $6.0 billion in 2023, then sank by 72.24% to $1.7 billion in 2024, then surged by 746.4% to $14.1 billion in 2025, then sank by 80.15% to $2.8 billion in 2026.
• The last three EBT figures came in at $2.8 billion (Q2 2026), $3.9 billion (Q1 2026), and $14.1 billion (Q4 2025), per Business Quant data.